투자정보
We operate with trust and do the right thing
IR/PR Materials
-
2024.10.01학술자료Novel Small-Molecule ROCK2 Inhibitor GNS-3595 Attenuates Pulmonary Fibrosis in Preclinical Studies
-
2023.05.22학술자료Novel Small Molecule ROCK Inhibitor GNS-3595 Attenuates Idiopathic Pulmonary Fibrosis Progression in Preclinical Models
-
2022.12.03학술자료ESMO ASIA 2022: A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation
-
2020.09.20학술자료ESMO 2020: Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
-
2019.12.01학술자료Lancet: Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label...
-
2019.01.22학술자료Clinical Cancer Research: YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer
